Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, 00168, Italy.
UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A Gemelli - IRCCS, Rome, 00168, Italy.
Immunotherapy. 2023 Dec;15(18):1521-1529. doi: 10.2217/imt-2023-0078. Epub 2023 Oct 18.
Baricitinib is a JAK1-2 inhibitor recently approved in Europe and Japan for the treatment of moderate-to-severe atopic dermatitis in adult patients at doses of 2 and 4 mg daily. The aim of this article is to discuss the safety profile of baricitinib in atopic dermatitis using data from clinical trials and the supporting literature, with a focus on infectious adverse events. An integrated analysis of safety data from eight clinical trials described infections as the most frequent treatment-emergent adverse events, mainly of mild-to-moderate severity, notably upper respiratory tract infections and herpes simplex exacerbations. Real-world data are still limited and will contribute to precisely profile the patients that might benefit from this treatment.
巴瑞替尼是一种 JAK1-2 抑制剂，最近在欧洲和日本获批用于治疗成人中重度特应性皮炎，剂量为每日 2 毫克和 4 毫克。本文旨在使用临床试验和相关文献数据讨论巴瑞替尼在特应性皮炎中的安全性概况，重点关注感染不良事件。对八项临床试验的安全性数据进行综合分析显示，感染是最常见的治疗中出现的不良事件，主要为轻度至中度严重程度，尤其是上呼吸道感染和单纯疱疹恶化。真实世界的数据仍然有限，将有助于更准确地确定可能从这种治疗中获益的患者。
